Investigational drug · Phase 2
SAL0137
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Elevated Lipoprotein(a).
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SAL0137"
First trial start
2026
Jul 27, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SAL0137", any sponsor or status.
Conditions studied
As listed on its trial records.
- Elevated Lipoprotein(a)
Largest trials
Live from ClinicalTrials.gov: studies naming "SAL0137" as an intervention, largest first.
- SAL0137 Phase I Study in in Healthy Participants With or Without Elevated Lp(a)Pivotal-lookingActive, not recruiting
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07745114 · 144 participants (planned) · Start Jan 4, 2026 · Primary completion Sep 30, 2026
Drug: Single Ascending Dose; Single Ascending Dose and 2 more · For: Healthy Participants; Elevated Lp(a)
Sites: Hefei, China
- A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular EventsPivotal-lookingNot yet recruiting
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07729475 · 120 participants (planned) · Start Jul 27, 2026 · Primary completion Dec 12, 2026
Drug: SAL0137 Dose 1; SAL0137 Dose 2 and 2 more · For: Elevated Lipoprotein(a)
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.